Roivant Sciences (ROIV) Competitors

BioNTech (NASDAQ:BNTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Does the MarketBeat Community prefer BNTX or ROIV?

BioNTech received 93 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 47.44% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 148 47.44%	Underperform Votes 164 52.56%
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%

Is BNTX or ROIV more profitable?

BioNTech has a net margin of -15.16% compared to Roivant Sciences' net margin of -119.54%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Roivant Sciences	-119.54%	-14.05%	-12.81%

Do analysts rate BNTX or ROIV?

BioNTech presently has a consensus price target of $142.08, suggesting a potential upside of 39.68%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 58.51%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of BNTX or ROIV?

15.5% of BioNTech shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 7.9% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, BNTX or ROIV?

BioNTech has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Which has better earnings & valuation, BNTX or ROIV?

Roivant Sciences has lower revenue, but higher earnings than BioNTech. Roivant Sciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	8.90	$1.01B	-$3.40	-29.92
Roivant Sciences	$122.59M	64.26	$4.35B	-$0.15	-73.60

Does the media favor BNTX or ROIV?

In the previous week, BioNTech had 9 more articles in the media than Roivant Sciences. MarketBeat recorded 22 mentions for BioNTech and 13 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.44 beat BioNTech's score of 1.19 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	11 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Roivant Sciences on 10 of the 18 factors compared between the two stocks.